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Leptin is a 16-kDa-peptide hormone that is primarily synthesized and secreted by adipose tissue. One of the major actions of
this hormone is the control of energy balance by binding to receptors in the hypothalamus, leading to reduction in food intake
and elevation in temperature and energy expenditure. In addition, increasing evidence suggests that leptin, through both direct
and indirect mechanisms, may play an important role in cardiovascular and renal regulation. While the relevance of endogenous
leptin needs further clariﬁcation, it appears to function as a pressure and volume-regulating factor under conditions of health.
However, in abnormal situations characterized by chronic hyperleptinemia such as obesity, it may function pathophysiologically
for the development of hypertension and possibly also for direct renal, vascular, and cardiac damage.
1.Introduction
The prevalence of obesity in the adult population of the
United States has risen markedly in the last three decades,
contributing to the increased incidence of diabetes, hyper-
tension, and heart disease [1–3]. Indeed, epidemiological
studies suggest that 65–75% of the risk for hypertension
is attributed to excess weight [4, 5]. Recently, a novel and
most promising area of research in obesity and hyper-
tension that links these two pathologic conditions is the
endocrinology of adipose tissue. It is now apparent that
adipose tissue is a proliﬁc organ which secretes several
immunomodulators and bioactive molecules [3, 6]. Of these
variousfactors,leptinhasemergedasanimportanthormone
with signiﬁcant pleiotropic actions on several organ systems
[7, 8].
The ﬁrst described major action of leptin was on the
hypothalamus to control body weight and fat deposition
through its eﬀects on appetite inhibition, as well as stim-
ulation of the metabolic rate and thermogenesis [9, 10].
However, increasing evidence suggests that the biology of
leptin extends to other organs including the kidney, the
heart, the sympathetic nervous system, and the systemic
vasculature, areas in which it may have prominent eﬀects
[7, 8, 11–14].
2.LeptinReceptors:LocalizationandFunction
The leptin receptor (LR), a product of the lepr gene,
is a member of the extended class I cytokine receptor
family having at least six splice variants LR (a-f) [15–19].
Signiﬁcant expression of the lepr gene occurs in the lung
and adipocytes, while only moderate levels appear in the
kidney, with relatively lower levels demonstrated in other
tissues like the heart, brain, spleen, liver, and muscle [20].
Though the extracellular domain of the leptin receptor
and the short splice variant (LRa) have been detected in
many peripheral tissues, the long splice variant (LRb) is
expressedinfewerorgansystemsincludingtheadrenalgland,
kidney, and heart [20]. This long splice variant leads to
activation of the Janus Kinases (a family of tyrosine kinases)2 International Journal of Hypertension
to promote transcription through activation of the STAT-
3 (signal transduction and activator of transcription) and
PI3K (phosphoinositol-3 kinase), and inhibition of AMPK
(AMP-activated protein kinase) [15–20]. LRa and LRb can
also stimulate MAPK (mitogen activated protein kinase)
which may be involved in the induction of hypertrophy [21].
Finally, SOCS-3 (suppression of cytokine signaling protein)
and PTB1b (protein tyrosine phosphatase 1b) have been
identiﬁed as negative regulators of leptin signaling [15–19].
3.Leptin,Sympathetic NervousSystem,and
the Regulation of ArterialBlood Pressure
It is now well established that leptin can activate the sympa-
thetic nervous system both by local peripheral actions as well
as through centrally mediated eﬀects on the hypothalamus
[22]. Studies with direct infusion of leptin into the cerebral
ventricles of normal rats have demonstrated a slow increase
of mean arterial pressure (MAP) of approximately 10%
[13]. Moreover, recent investigations have suggested that
leptin signaling in the nucleus tracti solitarii increased renal
sympathetic ﬂow in normal rats but not in obese Zucker rats,
indicating that intact leptin receptors are essential for this
vasoactive response [22]. In agreement with these concepts,
human studies have suggested that genetically mediated
leptin deﬁciency is associated not only with morbid obesity,
but also impairment in the sympathetic nervous system
activity and postural hypotension in homozygous children
and adults [23].
However, it is important to point out that in other
investigations conducted both in normotensive as well as
hypertensive rats [12, 14, 24], the acute systemic administra-
tion of leptin was associated with the peripheral activation
of the sympathetic nervous system without elevation in
MAP. This raises the possibility of the simultaneous local
activation of counter-regulatory vasodilatory mechanisms
[14, 25, 26]. In vitro studies have demonstrated a dose-
dependent leptin-induced vasorelaxation in the aortic rings
of Wistar-Kyoto rats [25] which is mediated by nitric oxide
(NO) and possibly by endothelial-derived hyperpolarizing
factor (EDHF). An elevation in plasma NO with intravenous
administration of synthetic leptin in normal rats has also
been demonstrated [26]. In these studies blockade of NO led
to a leptin-induced enhancement of arterial blood pressure
while blockade of the sympathetic nervous system led to
leptin-mediated reduction in blood pressure [26]. Thus,
leptin’s lack of eﬀect on arterial blood pressure in normal
subjects may represent a balanced action of vasodilatation
primarily mediated by NO and vasoconstriction primarily
mediatedbythesympatheticnervoussystem,witharesultant
neutral hemodynamic eﬀect [26, 27]. This concept requires
further validation because the vasodilatory actions of leptin
in other vascular beds have been found to be inconsistent
[28, 29]. In high-calorie fed obese rats, however, recent
studies by Beltowski et al have indicated that acutely infused
leptin was associated with a hypertensive eﬀect related, at
least in part, to impaired vascular NO and EDHF production
characteristic of obesity [30].
4. ChronicHyperleptinemia,LeptinResistance,
and Hypertension
In chronic hyperleptinemic conditions such as obesity, the
potential neutral eﬀect of leptin on peripheral vascular
resistance may no longer be present. It has been previously
demonstrated that the agouti yellow obese mouse model
is resistant to the satiety actions of leptin but not to
the eﬀects of leptin on the sympathetic nervous system
[31, 32], although this stimulation may be attenuated with
the progression of obesity [33]. From these ﬁndings, the
concept of “selective leptin resistance” as a mechanism for
the development of hypertension in obesity has emerged
[31, 32]. The precise factors behind this selectivity are yet
to be fully deﬁned [32, 34], but may involve alterations
in the SOCS3 signaling pathway or IRS-1 (insulin receptor
substrate-1) serine residue phosphorylation [30, 35, 36].
Independent of the possibility of selective leptin resis-
tance in obesity, studies in normal rats have demonstrated
that chronic hyperleptinemia leads to a persistent elevation
in MAP and this hypertensive eﬀect is rapidly reversed
upon cessation of the hormone administration [37]. Similar
increases in systolic blood pressure have been demonstrated
in transgenic mice overexpressing leptin where the endoge-
nous level of the hormone was elevated twenty-fold [38]. In
this regard, it is pertinent to point out that hyperleptinemia
may increase vascular smooth muscle cell proliferation [38],
an eﬀect that could contribute to the development and/or
perpetuation of hypertension. Moreover, mice with leptin
deﬁciency (ob/ob) or with a leptin receptor defect (db/db)
exhibit signiﬁcant obesity but do not develop hypertension,
suggesting that at least in animal models, leptin may play
a role in the regulation of systemic hemodynamics [32]. In
humans, emerging evidence suggests a direct relationship
between hyperleptinemia and hypertension in both men and
women [39, 40], and this eﬀect may be independent of
BMI and insulin resistance. In a recent study by Shankar
and Xiao of 5,599 Americans, higher plasma leptin levels
were positively associated with hypertension after adjusting
for multiple covariates including age, sex, race/ethnicity,
education, smoking, body mass index, diabetes mellitus,
and serum cholesterol [41]. In this regard, recent studies
indicating a reduction in serum leptin levels with the use of
angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers suggest a potential interaction between
leptin and the renin-angiotensin-aldosterone system for
hemodynamic regulation in obesity [42, 43].
Finally, an additional potential mechanism involved
in leptin’s regulation of blood pressure implicates the
melanocortin system [44]. Recent investigations have sug-
gested that the acute actions of leptin to raise renal sym-
pathetic activity are abolished in Melanocortin 4 receptor-
(MC4R-) deﬁcient (−/−) mice, suggesting that the MC4R
may mediate the sympathoexcitatory actions of leptin [45].
Tothisend,Greenﬁeldetal.demonstratedalowerprevalence
of hypertension in obese subjects with a loss-of-function
mutationinMC4Rgenecomparedtoobesecontrolswiththe
intact gene again implicating melanocortinergic signaling in
the control of systemic hemodynamics [46].International Journal of Hypertension 3
5. Leptin andthe Regulation of
Sodium-Volume Balance
Previous studies have indicated that the LRb leptin receptor
is localized in the renal medulla [20, 47] which suggests
a functional role of this hormone in renal biology. In the
last 5–10 years, numerous studies have demonstrated that
acute administration of synthetic leptin in the rat produces
a signiﬁcant elevation in urinary sodium and water excretion
[14, 47–49].
Villarreal et al. [14] demonstrated that in normotensive
rats, an intravenous bolus of leptin produced a robust six
to sevenfold elevation in urinary sodium excretion and
fractional excretion of sodium; in contrast, hypertensive rats
were refractory to the renal eﬀects of leptin. Interestingly,
the natriuretic eﬀect was attenuated in obese Zucker rats
[14]. MAP and creatinine clearance remained unchanged
in all of the rat strains with the acute infusion of the
hormone. Collectively, these ﬁndings were interpreted to
suggest that leptin might be a natriuretic hormone primarily
acting at the tubular level for promotion of sodium and
water excretion in normal rats, and that leptin may function
pathophysiologically in obesity and hypertension, where
chronic hyperleptinemia may contribute to a preferential
stimulation of the sympathetic nervous system with further
elevation in blood pressure and reduced sodium and water
excretion [2, 7, 50]. Moreover, in a rat model of diet-induced
obesity, initial studies by Patel et al. have shown markedly
attenuated natriuretic and diuretic eﬀects of synthetic leptin
as well as reduced urinary excretion of NO [51]. These
ﬁndings suggest that in obesity, alterations in leptin-induced
renal NO production and/or metabolism may account, at
least in part, for the blunted natriuretic eﬀects. However,
additional observations in diet-induced obese rats indicate
that caloric restriction was associated with the restoration
of the natriuretic actions of leptin as well as with the renal
generation of NO [51]. In the aggregate, these studies are
consistent with the concept that obesity is associated with
renal leptin resistance [14, 52], and this resistance, at least
in part, is reversible with caloric restriction and weight loss.
The signiﬁcance of NO in the direct modulation of
leptin-induced sodium excretion has been investigated in
rats chronically treated with L-NAME to inhibit NO produc-
tion [53]. L-NAME-treated rats failed to produce signiﬁcant
natriuresis. However, there was a two to threefold elevation
in sodium excretion induced by leptin with the restoration
of NO by sodium nitroprusside [53], indicating that NO
may play an important role in mediating or modulating
the tubular natriuretic eﬀects of leptin. These observations
are supported by the studies of Beltowski et al., [52]
which demonstrated that leptin produces a time- and
dose-dependent reduction of renal medullary Na-K-ATPase,
which may in part be regulated by NO [53, 54]. Beltowski et
al., [52] also reported that in diet-induced obese rats, leptin-
induced stimulation of plasma NO, reduction of renal Na-K-
ATPase, and natriuresis are all signiﬁcantly impaired.
The mechanisms for renal resistance to leptin in obesity
and hypertension are not completely deﬁned but may
include receptor down regulation [12, 51], postreceptor
signaling alterations [12, 16, 17], excessive degradation of
NOproducedbyoxidativestress[55],orincreasedactivation
of the eﬀerent renal sympathetic nervous system leading
to antinatriuresis [49]. Indeed, studies which [49]h a v e
examined this latter hypothesis using an animal model of
renal denervation indicate that the renal eﬀerent sympa-
thetic nervous system is an important counter-regulatory
mechanism impeding leptin-induced sodium excretion in
hypertension, and perhaps also during obesity, which is
similarly characterized by a heightened sympathetic nervous
tone [2, 7].
The relevance of endogenous leptin as a distinct sodium-
volume regulatory hormone has been examined in nor-
mal Sprague Dawley rats that were in a state of mild
sodium/volumeexpansion[56].Urinarysodiumandvolume
excretion were signiﬁcantly reduced by approximately 20–
25% after blockade of leptin with a polyclonal antibody,
indicating an important physiologic role for this hormone
in the daily renal control of salt and water balance. The
importance of leptin as a regulator of sodium and volume
is further supported by recent investigations [56, 57]w h i c h
have demonstrated that leptin expression in adipose tissue
is directly proportional to dietary sodium, a response
that would be expected for mechanisms regulating sodium
balance.
Thus, the available information to date suggests that
leptin’sneteﬀectonrenalsodiummetabolismandultimately
systemic hemodynamics may reﬂect both direct natriuretic
and indirect antinatriuretic actions. The responsiveness to
leptin at neural, renal, and other sites which regulate
natriuresis and vascular resistance may diﬀer under diverse
physiological and pathophysiological conditions, and this in
turn, will be a determinant for the overall magnitude of
leptin-induced sodium, water, and hemodynamic balance.
6. LeptinandChronicRenal Insufﬁciency
Leptin’s role in renal physiology and pathophysiology is
complex. As previously discussed, leptin may play a signif-
icant role in the regulation of sodium and water balance
in normal situations. However, in conditions of chronic
hyperleptinemia, the hormone has been linked to renal
structural changes that speciﬁcally have been associated
with obesity [58] .E l e g a n ts t u d i e sb yW o l fe ta l .[ 59]h a v e
determined that in glomerular endothelial cells, leptin can
stimulate cellular proliferation, expression of TGF-β1a n d
typeIVcollagensynthesisleadingtoﬁbrosis.Indeed,chronic
infusion of leptin in normal rats promoted the development
of glomerulosclerosis and proteinuria [59]. It is of interest
that similar renal abnormalities have been found in mice
with chronic high fat diet and the metabolic syndrome [60],
which is characterized by sustained elevations of circulating
leptin [61].
Inappropriate elevation in serum leptin levels has been
demonstrated in patients with chronic kidney disease [62–
64]. The origin and signiﬁcance of hyperleptinemia in these
patients are not completely deﬁned, but it is important to
emphasize that the marked elevation of leptin is out of4 International Journal of Hypertension
proportion to obesity and persists after correction for body
mass index [65]. Since the kidney is involved in clearance of
leptin, its elevated levels in renal insuﬃciency are primarily
due to reduced renal ﬁltration and metabolism [62, 66]. It
remains to be determined whether an increased rate of leptin
production also contributes to the high serum leptin levels in
renal insuﬃciency.
Leptin levels appear to be higher in patients receiving
peritoneal dialysis (PD) compared to hemodialysis (HD)
[67]. The reasons for this phenomenon are multifactorial. It
is likely that the elevated body fat mass in patients with PD
contributes to the increase in serum leptin [67]. However,
other factors are probably involved. For instance, the contin-
uous glucose load in PD results in chronic hyperinsulinemia,
an important ﬁnding considering that insulin upregulates
lepr gene expression [63]. In this regard, it is of interest
that even higher leptin levels are observed in patients with
renal insuﬃciency with elevated insulin levels compared to
patients with low insulin levels [63, 68].
The pathophysiological signiﬁcance of hyperleptinemia
in renal insuﬃciency is not completely understood. High
levels of leptin have been associated with weight loss in
dialysis patients [65, 69–71], and therefore it has been
suggested that hyperleptinemia may be a contributing factor
in uremic-induced cachexia [64, 69–74]. Other suggested
actions in patients with end-stage renal disease which
include leptin-induced reduction in erythropoiesis [75, 76],
promotion of renal osteodystrophy [77, 78], and chronic
inﬂammation [63, 78, 79].
7.LeptinandtheHeart
It is now well recognized that the role of leptin in energy
homeostasis extends into cardiac metabolism. The eﬀects of
leptin mediated by the LRb receptor include a reduction of
insulinsignalingwithenhancedlipidoxidationandtherefore
inhibition of anabolic pathways [80]. Similar to the kidney,
chronic hyperleptinemia may be indirectly important in the
development of cardiac disease via sympathetic activation,
pressor eﬀects, enhancement of platelet aggregation, impair-
ment of ﬁbrinolysis as well as proangiogenic actions [12,
35, 81, 82] and systemic inﬂammation via leptin-induced
expression of C-reactive protein [83, 84].
In addition, and although still controversial, leptin may
be involved in the pathogenesis of myocyte hypertrophy
and cardiac dysfunction [85–87] through direct eﬀects.
Indeed, leptin can proliferate, diﬀerentiate, and function-
ally activate hemopoietic and embryonic cells to promote
myocyte growth [88–90]. Moreover, in rats with myocardial
infarction, cardiac hypertrophy has been shown to be
attenuatedwiththeblockadeofleptinreceptors[91].Among
the suggested mechanisms of leptin-induced hypertrophy
are the stimulation of endothelin-1, angiotensin II [92],
and reactive oxygen species [93]. Additional studies in rats
with myocardial infarction have also indicated that long-
term continuous administration of leptin promoted the
development of eccentric cardiac hypertrophy [94].
In contrast to these investigations, studies in leptin-
deﬁcient mice (ob/ob) with [94, 95] or without myocardial
infarction[96]havesuggestedthatleptincanexertprotective
cardiac eﬀects with reversal of baseline myocyte hypertro-
phy during leptin supplementation [96]. Also, Tajmir et
al. [97] have indicated that leptin can activate ERK 1/2
(extracellular signal-regulated kinase) and phosphoinositol-
3 kinase-dependent signaling pathways in cardiomyocytes
to promote physiological repair of myocardium. Presently,
the reasons for the apparent discrepant eﬀects of leptin
on myocyte growth are unclear, but may be related to
diﬀerent experimental conditions, including the variable
response of leptin in neonatal compared to adult cells
[82–97].
In addition to its potential actions on myocardial cell
growth, leptin has been shown to exert direct negative
inotropic eﬀects on adult rat ventricular myocytes [98].
The suggested mechanisms involve activation of fatty acid
oxidation leading to decreased triglyceride content or an
altered adenylate cyclase function [96, 99]. Alternatively,
Nickola et al. [98] reported that leptin may abnormally
increase expression of Nitric Oxide Synthases in cardiac
myocytes promoting oxidative stress and depressed cardiac
function. However, similar to the controversy related to
cardiac hypertrophy, more recent studies in ob/ob mice
[95]o rr a t s[ 94] with myocardial infarction have suggested
that leptin may attenuate adverse cardiac remodeling by
reducing apoptosis [95], which may improve left ventricular
contractile function, and at least in part, increase survival
[94–96].
The relevance of these studies in humans is unclear.
Although there is evidence to suggest a direct relationship
between the hyperleptinemia of obesity with cardiac hyper-
trophy [96, 100], and possibly heart failure [101], these are
not consistent ﬁndings [8, 11]. Additional in vitro and in vivo
studies are needed to deﬁne and characterize the potential
beneﬁcialordeleteriouseﬀectsofleptinincardiacphysiology
and pathophysiology.
8. Summary and Conclusions
It is well established that cardiovascular and renal functions
require the activation of multiple neuro hormonal mech-
anisms designed to maintain homeostasis. The hormone
leptin has multiple actions that may be important not only
for energy metabolism, but also in physiological and patho-
physiological cardiovascular and renal regulation (Figure 1).
Potentially prominent are its eﬀects on renal sodium
excretion, NO, sympathetic nervous system activation, and
vascular tone. The interaction among the vasoconstricting,
vasodilatory, and natriuretic eﬀects of leptin to help achieve
volume and pressure homeostasis in normal conditions may
be disrupted during chronic hyperleptinemia, and this eﬀect
could likely contribute to hypertension and possible cardiac
and renal dysfunction. Further research awaits the additional
characterization of both direct and indirect mechanisms of
action of leptin, including its interface with other important
hormonal sodium-volume-pressure regulatory systems, in
both health and disease states, particularly obesity and
related comorbidities.International Journal of Hypertension 5
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Figure 1: Cardiovascular and Renal Actions of Leptin. SNS: sympathetic nervous system. Adapted from Kshatriya S, Reams GP, Spear RM,
Freeman RH, Dietz JR, Villarreal D. Current Opinion in Nephrology and Hypertension, 2010 Jan; 19 (1): 72−8. With Permission from
Wolters Kluwer/Lippincott, Williams & Wilkins.
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